The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
UCB and Dermira are expecting to file anti-inflammatory Cimzia for psoriasis in the third quarter of this year, after the drug’s strong performance in a late-stage trial involving patients with severe chronic plaque forms of the skin disease.